嵌合乙型肝炎病毒（HBV）/丙型肝炎病毒（HCV）亚病毒包膜颗粒在预先接种乙肝疫苗的动物中可诱导高效的抗丙肝病毒抗体产生。
Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.
作者信息
Beaumont Elodie, Roingeard Philippe
机构信息
INSERM U966, Université François Rabelais and CHRU de Tours, 10 bld Tonnelle, Tours, France.
INSERM U966, Université François Rabelais and CHRU de Tours, 10 bld Tonnelle, Tours, France.
出版信息
Vaccine. 2015 Feb 18;33(8):973-6. doi: 10.1016/j.vaccine.2015.01.007. Epub 2015 Jan 14.
Abstract
The development of an effective, affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. The recently described chimeric HBV-HCV subviral envelope particles could potentially be used for this purpose, as they could be produced by industrial procedures adapted from those established for the hepatitis B virus (HBV) vaccine. We show here, in an animal model, that pre-existing immunity acquired through HBV vaccination does not influence the immunogenicity of the HCV E2 protein presented by these chimeric particles. Thus, these chimeric HBV-HCV subviral envelope particles could potentially be used as a booster in individuals previously vaccinated against HBV, to induce protective immunity to HCV.
摘要
开发一种有效且价格合理的丙型肝炎病毒（HCV）预防性疫苗仍是医学上的一项优先任务。最近描述的嵌合型乙肝病毒-丙肝病毒亚病毒包膜颗粒有可能用于此目的，因为它们可以通过借鉴乙肝病毒（HBV）疫苗的现有工业生产流程来制备。我们在此动物模型中表明，通过接种乙肝疫苗获得的既往免疫力不会影响这些嵌合颗粒所呈现的丙肝病毒E2蛋白的免疫原性。因此，这些嵌合型乙肝病毒-丙肝病毒亚病毒包膜颗粒有可能用作曾接种过乙肝疫苗个体的加强针，以诱导对丙肝病毒的保护性免疫。
相似文献
1
Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.嵌合乙型肝炎病毒（HBV）/丙型肝炎病毒（HCV）亚病毒包膜颗粒在预先接种乙肝疫苗的动物中可诱导高效的抗丙肝病毒抗体产生。
Vaccine. 2015 Feb 18;33(8):973-6. doi: 10.1016/j.vaccine.2015.01.007. Epub 2015 Jan 14.
2
Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.嵌合乙型肝炎病毒/丙型肝炎病毒包膜蛋白可诱导广泛中和抗体，并构成潜在的双价预防性疫苗。
Hepatology. 2013 Apr;57(4):1303-13. doi: 10.1002/hep.26132. Epub 2013 Mar 14.
3
4
Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy.将载脂蛋白 E 纳入 HBV-HCV 亚病毒包膜颗粒以改进肝炎疫苗策略。
Sci Rep. 2021 Nov 8;11(1):21856. doi: 10.1038/s41598-021-01428-7.
5
Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.嵌合乙型肝炎病毒表面抗原病毒样颗粒诱导的抗体对丙型肝炎病毒中和表位的中和作用。
Vaccine. 2018 Apr 19;36(17):2273-2281. doi: 10.1016/j.vaccine.2018.03.036. Epub 2018 Mar 22.
6
DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.用编码丙型肝炎病毒E2不同区域并与乙型肝炎表面抗原基因融合的融合基因进行DNA免疫接种，可引发针对丙型肝炎病毒和乙型肝炎病毒的免疫反应。
World J Gastroenterol. 2002 Jun;8(3):505-10. doi: 10.3748/wjg.v8.i3.505.
7
Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.在表位呈递系统中展示的丙型肝炎病毒/乙型肝炎病毒表位的免疫反应性。
Mol Immunol. 2006 Feb;43(5):436-42. doi: 10.1016/j.molimm.2005.03.002. Epub 2005 Apr 2.
8
Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus.暴露丙型肝炎病毒高度保守E2表位的利什曼原虫源性乙型肝炎小表面抗原颗粒的免疫原性
Microb Cell Fact. 2016 Apr 13;15:62. doi: 10.1186/s12934-016-0460-4.
9
Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.用于慢性乙型肝炎病毒感染的基于病毒样囊泡的治疗性疫苗载体
J Virol. 2015 Oct;89(20):10407-15. doi: 10.1128/JVI.01184-15. Epub 2015 Aug 5.
10
Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies.嵌合型乙肝和丙肝病毒包膜蛋白可形成亚病毒颗粒：对新型疫苗策略设计的启示
N Biotechnol. 2009 Apr;25(4):226-34. doi: 10.1016/j.nbt.2009.01.001. Epub 2009 Jan 21.
引用本文的文献
1
Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies.基于诱导中和抗体的当前丙型肝炎疫苗候选物。
Viruses. 2023 May 11;15(5):1151. doi: 10.3390/v15051151.
2
Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector.野生型和突变型乙型肝炎表面抗原病毒样颗粒（VLPs）在对野生型载体具有预先存在免疫的小鼠中的免疫原性。
Viruses. 2023 Jan 23;15(2):313. doi: 10.3390/v15020313.
3
Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy.将载脂蛋白 E 纳入 HBV-HCV 亚病毒包膜颗粒以改进肝炎疫苗策略。
Sci Rep. 2021 Nov 8;11(1):21856. doi: 10.1038/s41598-021-01428-7.
4
To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.纳入或排除：HCV 疫苗体液免疫的理性工程。
Viruses. 2021 Apr 30;13(5):805. doi: 10.3390/v13050805.
5
Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.乙型肝炎病毒（HBV）亚病毒颗粒作为保护性疫苗和疫苗平台。
Viruses. 2020 Jan 21;12(2):126. doi: 10.3390/v12020126.
6
SnoopLigase peptide-peptide conjugation enables modular vaccine assembly.SnoopLigase 肽-肽偶联能够实现模块化疫苗组装。
Sci Rep. 2019 Mar 15;9(1):4625. doi: 10.1038/s41598-019-40985-w.
7
Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.作为丙型肝炎疫苗候选物的病毒样颗粒的临床前开发与生产
Front Microbiol. 2017 Dec 5;8:2413. doi: 10.3389/fmicb.2017.02413. eCollection 2017.
8
The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.预防性丙型肝炎病毒样颗粒（VLP）疫苗的理论依据。
Front Microbiol. 2017 Nov 7;8:2163. doi: 10.3389/fmicb.2017.02163. eCollection 2017.
9
Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8 T-cell response.细胞穿透衣壳作为通用抗原载体诱导抗原特异性 CD8 T 细胞应答。
Sci Rep. 2017 Aug 29;7(1):9630. doi: 10.1038/s41598-017-08787-0.
10
Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus.暴露丙型肝炎病毒高度保守E2表位的利什曼原虫源性乙型肝炎小表面抗原颗粒的免疫原性
Microb Cell Fact. 2016 Apr 13;15:62. doi: 10.1186/s12934-016-0460-4.
本文引用的文献
1
Response to booster doses of hepatitis B vaccine among young adults who had received neonatal vaccination.接受过新生儿期乙肝疫苗接种的年轻成年人对乙肝疫苗加强剂量的反应。
PLoS One. 2014 Sep 8;9(9):e107163. doi: 10.1371/journal.pone.0107163. eCollection 2014.
2
Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.2006-2012 年美国非城市地区年轻静脉注射吸毒者中丙型肝炎病毒感染的新出现流行。
Clin Infect Dis. 2014 Nov 15;59(10):1411-9. doi: 10.1093/cid/ciu643. Epub 2014 Aug 11.
3
Hepatitis B virus infection.乙型肝炎病毒感染。
Lancet. 2014 Dec 6;384(9959):2053-63. doi: 10.1016/S0140-6736(14)60220-8. Epub 2014 Jun 18.
4
Bioengineering virus-like particles as vaccines.生物工程病毒样颗粒作为疫苗。
Biotechnol Bioeng. 2014 Mar;111(3):425-40. doi: 10.1002/bit.25159. Epub 2013 Dec 17.
5
Treatment as prevention and cure towards global eradication of hepatitis C virus.治疗即预防，努力实现全球丙型肝炎病毒消除。
Trends Microbiol. 2013 Dec;21(12):625-33. doi: 10.1016/j.tim.2013.09.008. Epub 2013 Nov 14.
6
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.了解丙型肝炎病毒的生命周期为高效疗法铺平了道路。
Nat Med. 2013 Jul;19(7):837-49. doi: 10.1038/nm.3248.
7
The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease.美国丙型肝炎病毒感染的隐匿性流行：隐匿传播与疾病负担
Top Antivir Med. 2013 Feb-Mar;21(1):15-9.
8
Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine.预先存在的抗载体免疫和抗原元件多样性对模块化病毒样颗粒疫苗效力的影响。
Biotechnol Bioeng. 2013 Sep;110(9):2343-51. doi: 10.1002/bit.24907. Epub 2013 Apr 22.
9
Prospects for prophylactic hepatitis C vaccines based on virus-like particles.基于病毒样颗粒的丙型肝炎预防性疫苗的前景。
Hum Vaccin Immunother. 2013 May;9(5):1112-8. doi: 10.4161/hv.23900. Epub 2013 Feb 13.
10
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.全球丙型肝炎病毒感染的流行病学：特定年龄组丙型肝炎病毒抗体血清流行率的新估计。
Hepatology. 2013 Apr;57(4):1333-42. doi: 10.1002/hep.26141. Epub 2013 Feb 4.
Zotero 插件